Effect of fluoxetine on the pharmacokinetics of lansoprazole: A two-treatment period study in healthy male subjects

Clinical Drug Investigation

Volumn 31, Issue 10, 2011, Pages 727-733

  Vlase, Laurian ^a   Popa, Adina ^a   Neag, Maria ^a   Muntean, Dana ^a   Leucuta, Sorin E ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Drug interactions; Fluoxetine; Lansoprazole; Proton pump inhibitors; Serotonin uptake inhibitors

Indexed keywords

FLUOXETINE; FLUOXIN; LANSOPRAZOLE; LEVANT; NORFLUOXETINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FATIGUE; HEARTBURN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; DRUG INTERACTIONS; FLUOXETINE; HUMANS; MALE;

EID: 80052498075     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11589010-000000000-00000     Document Type: Article

References (26)

1. Gremse DA. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert Opin Pharmacother 2001; 2 (10): 1663-70 (Pubitemid 33019734)
2. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935-51
3. Product monograph. Prevacid®, lansoprazole. Saint-Laurent, Canada: Abbott Laboratories, Limited (revised 9/2008, cited 7/2010) [online]. Available from URL: . abbott.ca/static/cms-workspace/en-CA/content/document/ Prevacid-PM-01-NOV-10.pdf [Accessed 2011 Jul 13]
4. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44 (7): 297-302 (Pubitemid 44043771)
5. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63 (24): 2739-54 (Pubitemid 38049991)
6. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26 (3): 201-14 (Pubitemid 24081625)
7. AHFS Drug Information 2008. American Society of Health- System Pharmacists, Bethesda (MD)
8. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3 (1): 13-37 (Pubitemid 34296308)
9. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21 (Pubitemid 27107715)
10. Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34 (4): 281-302 (Pubitemid 28163404)
11. Full prescribing information. Prozac® fluoxetine. Eli Lilly and Company, Indianapolis, IN, USA (revised 9/2009, cited 11/2010) [online]. Available from URL: cessdata.fda.gov/drugsatfda-docs/label/2009/018936s075s 077lbl.pdf [Accessed 2011 Jul 13]
12. Bergstrom RF, Goldberg MJ, Cerimele BJ, et al. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 1997; 62 (6): 643-51 (Pubitemid 28068068)
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.Guidance: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1999 Nov
14. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2002 Jul
15. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. London: The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, 2001 Jul
16. Schuirmann DJ. A comparison of the two one-sided test procedure and the power approach for assessment of the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15 (6): 657-80
17. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995; 10 (1): 15-21
18. Potkin SG, Alva G, Kalali A, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002; 22 (2): 174-82 (Pubitemid 34289392)
19. Yasui-Furukori N, Saito M, Uno T, et al. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 2004; 44 (11): 1223-9 (Pubitemid 39391480)
20. Thomson ABR, Sauve MD, Kassam N, et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16 (19): 2323-30
21. Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50 (4): 366-72
22. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53 (Pubitemid 46021498)
23. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103: 2308-13
24. Wright MJ, Proctor DD, Insogna KL, et al. Proton pumpinhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008; 66: 103-8 (Pubitemid 351666656)
25. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-26
26. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19 (4): 299-320 (Pubitemid 34686722)